Charge-driven antiviral responses enhance autoreactivity in severe COVID-19
This study reveals that antiviral antibodies in severe COVID-19 acquire broad autoreactivity through a charge-driven mechanism, where affinity maturation enriches positively charged residues in antibody binding regions to target negatively charged viral and self-antigens.